A Deep Dive Into Treatment Approaches for Patients With MDS by Risk Status

Panelists discuss how treatment strategies for myelodysplastic syndromes (MDS) are fundamentally guided by risk stratification, with lower-risk patients typically receiving supportive care and less intensive treatments focused on quality of life and symptom management while intermediate- to high-risk patients require more aggressive approaches, including hypomethylating agents and consideration for stem cell transplantation, with emerging data supporting novel combinations and targeted therapies across the risk spectrum.

EP: 1.Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024

EP: 2.MDS Treatment Strategies: From Risk Assessment to Transplantation

EP: 3.Introducing Hypomethylating Agents for Patients With MDS

EP: 4.ASCERTAIN Trial: Key Data of Oral Decitabine and Cedazuridine in MDS

EP: 5.Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS

EP: 6.Clinical Insights: Key Data Presented at ASH 2024 in MDS

Now Viewing

EP: 7.A Deep Dive Into Treatment Approaches for Patients With MDS by Risk Status

EP: 8.Future Horizons in the Treatment of Myelodysplastic Syndromes

Video content above is prompted by the following:

Related Videos